The role of 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: Is it the new beginning.
作者信息
Agrawal Sumit
机构信息
Department of Urology, AIIMS, Bhubaneswar, Odisha, India.
出版信息
Indian J Urol. 2020 Jan-Mar;36(1):69-70. doi: 10.4103/iju.IJU_266_19.
Abstract
摘要
相似文献
1
The role of 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: Is it the new beginning.225Ac-PSMA-617在未经化疗的晚期前列腺癌患者中的作用：这是新的开端吗？
Indian J Urol. 2020 Jan-Mar;36(1):69-70. doi: 10.4103/iju.IJU_266_19.
2
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.225Ac-PSMA-617用于转移性去势抵抗性前列腺癌的PSMA靶向α放射治疗。
J Nucl Med. 2016 Dec;57(12):1941-1944. doi: 10.2967/jnumed.116.178673. Epub 2016 Jul 7.
3
Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Ac-PSMA-617 Radioligand Therapy.转移性去势抵抗性前列腺癌患者接受 Ac-PSMA-617 放射性配体治疗的总生存和无病生存的预测因素。
J Nucl Med. 2020 Jan;61(1):62-69. doi: 10.2967/jnumed.119.229229. Epub 2019 May 17.
4
Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.载 225Ac 抗前列腺特异性膜抗原脂质体用于潜在的靶向抗血管α粒子治疗癌症。
J Nucl Med. 2014 Jan;55(1):107-14. doi: 10.2967/jnumed.113.125476. Epub 2013 Dec 12.
5
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.转移性去势抵抗性前列腺癌的靶向 α 治疗：Ac-PSMA-617 的剂量估算和经验剂量探索。
J Nucl Med. 2017 Oct;58(10):1624-1631. doi: 10.2967/jnumed.117.191395. Epub 2017 Apr 13.
6
Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.前列腺特异性膜抗原PET成像在前列腺癌中的当前应用及未来展望
Q J Nucl Med Mol Imaging. 2019 Mar;63(1):7-18. doi: 10.23736/S1824-4785.18.03059-5. Epub 2018 Mar 8.
7
Clinical Outcomes of Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy.Lu-PSMA 放射性配体疗法在转移性去势抵抗性前列腺癌不同阶段（按既往紫杉烷化疗分组）的临床结局。
J Nucl Med. 2019 Jul;60(7):955-962. doi: 10.2967/jnumed.118.216820. Epub 2019 Jan 25.
8
New aspects of molecular imaging in prostate cancer.前列腺癌分子影像学的新方面。
Methods. 2017 Nov 1;130:36-41. doi: 10.1016/j.ymeth.2017.07.009. Epub 2017 Jul 13.
9
Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.先进前列腺癌的治疗策略：当前的适应证和未来的发展。
Eur Urol Oncol. 2019 Mar;2(2):152-162. doi: 10.1016/j.euo.2019.01.001. Epub 2019 Jan 31.
10
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.BIND-014 治疗转移性去势抵抗性前列腺癌的安全性和疗效：一项针对前列腺特异性膜抗原的紫杉醇纳米颗粒的 2 期临床试验。
JAMA Oncol. 2018 Oct 1;4(10):1344-1351. doi: 10.1001/jamaoncol.2018.2168.
引用本文的文献
1
PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?PSMA 靶向放射性核素治疗在现代核医学中的应用：过去、现在和未来？
Theranostics. 2024 May 13;14(8):3043-3079. doi: 10.7150/thno.92612. eCollection 2024.
2
Adoption of Lutetium- PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020.镥- PSMA 放射性配体疗法在转移性去势抵抗性前列腺癌中的应用：2016 年至 2020 年德国的全人群分析。
Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):2188-2195. doi: 10.1007/s00259-023-06139-x. Epub 2023 Feb 24.
3
Theragnostic Radionuclide Pairs for Prostate Cancer Management: Cu/Cu, Can Be a Budding Hot Duo.用于前列腺癌治疗的诊疗放射性核素对：铜/铜，可能成为一对崭露头角的热门组合。
Biomedicines. 2022 Nov 2;10(11):2787. doi: 10.3390/biomedicines10112787.
4
Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors.前列腺特异性膜抗原作为中枢神经系统肿瘤神经影像学的靶点。
Mol Imaging. 2022 Apr 15;2022:5358545. doi: 10.1155/2022/5358545. eCollection 2022.
5
Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches.前列腺特异性膜抗原靶向治疗学：过去、现在和未来的方法。
Clin Adv Hematol Oncol. 2022 Apr;20(4):227-238.
6
Advances in PSMA-targeted therapy for prostate cancer.前列腺癌 PSMA 靶向治疗的进展。
Prostate Cancer Prostatic Dis. 2022 Mar;25(1):11-26. doi: 10.1038/s41391-021-00394-5. Epub 2021 May 28.
7
Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer.用于转移性去势抵抗性前列腺癌的PSMA靶向α治疗的临床前和临床状况
Cancers (Basel). 2021 Feb 13;13(4):779. doi: 10.3390/cancers13040779.
本文引用的文献
1
Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.使用放射性标记的前列腺特异性膜抗原（PSMA）抑制剂对前列腺癌进行靶向α治疗：核医学领域的变革者。
Am J Nucl Med Mol Imaging. 2018 Aug 20;8(4):247-267. eCollection 2018.
2
Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.化疗初治的晚期前列腺癌患者中 Ac-PSMA-617 的初步研究。
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):129-138. doi: 10.1007/s00259-018-4167-0. Epub 2018 Sep 19.
3
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.225Ac-PSMA-617用于转移性去势抵抗性前列腺癌的PSMA靶向α放射治疗。
J Nucl Med. 2016 Dec;57(12):1941-1944. doi: 10.2967/jnumed.116.178673. Epub 2016 Jul 7.
Zotero 插件